| Prev Close | 44.13 |
| Open | 44.18 |
| Day Low/High | 43.67 / 44.20 |
| 52 Wk Low/High | 35.30 / 46.22 |
| Volume | 1.65M |
| Avg Volume | 3.45M |
AstraZeneca Plc (AZN)
43.87
0.26
0.59
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.62B |
| Market Cap | 114.91B |
| EPS | 0.80 |
| P/E Ratio | 19.79 |
| Div & Yield | 1.37 (3.10%) |
Shorting AZN
I doubt this story. A London Sunday Times article suggests that Pfizer (PFE) considered acquiring AstraZeneca (AZN), but the talks stalled and will not resume. I am doubtful of this story and I have shorted AZN, +$6 in premarket trading as the compa...
Array CEO: Partnerships Smart While Cancer Drug Develops
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart
James Molloy, Managing Director at Janney Montgomery Scott explains why Actavis buying Forest Labs is a smart for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
European Stocks Rally on Fed Guidance; Drugmakers Strike Deals
The U.K.'s AstraZeneca and Germany's Bayer spend up to a combined $7.2 billion shoring up their portfolios. Laura Board reports from London.
Keep Calm and Carry EWU
The UK is the next geographic hotspot. Play it with this ETF.
S&P Lifts U.S. Credit Outlook
Credit rating agency Standard & Poor's upgrades its credit outlook for the U.S. government to Stable from Negative.
Stocks Follow Japan's Lead Upward
Merger Monday begins with AstraZeneca buying Pearl, while Apple could announce iRadio and Google may purchase Waze as futures look up.
Millions for Fish Oil
Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.
The Biotech Revaluation Is On
These four names in particular have made some stunning moves.
Trending Now: HPQ Announces 10% Increase in Quarterly Dividend
Hewlett-Packard announces a 10% increase in its quarterly dividend. Brittany Umar has details on that as well as a look at the day's other most searched trends on the Web.
IPOs: LifeLock, Luxfer, Regulus
LifeLock looks to be the best offering for the IPOs planned on Wednesday according to IPO Desltop President Francis Gaskins.
Three U.K. Gold Medalists
These companies are performing like champions, despite a weak British economy.
Trading Abbott for Bristol Myers
Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.
Apple Pays Proview $60 Million in iPad Dispute: Hot Trends
A look at some of the day's most searched topics on the Web, includingApple as the company shells out $60 million to settle its iPad namingdispute with Proview Technology.
The Next Big Thing in Biotech: M&A
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends
A look at the day's most searched trends on the Web, including AstraZeneca's purchase of Ardea Biosciences for $1.26 billion.
The Day Ahead: Anticipating Economic Data
European headlines worried traders ahead of the open, as they await a raft of economic and retail reports.
Adding New Names to the Wish List
Net-cash stocks can be the Christmas gifts that keep on giving.
Finding an Antidote for Health Care
The sector is in the doldrums, yet the prospects for these three names are quite strong.
Portfolio Protection Is Paramount
Forget about hitting home runs and focus on avoiding strikeouts.
